ELUCIDATING THE MECHANISM OF RECEPTOR TYROSINE KINASE INHIBITION BY SOLUBLE LRIG1 IN GLIOBLASTOMA

被引：0
|
作者：
Tiemann, Katja [1 ]
Hedman, Hakan [2 ]
Niclou, Simone P. [1 ]
机构：
[1] CRP Sante, NorLux Neurooncol Lab, Dept Oncol, Luxembourg, Luxembourg
[2] Umea Univ, Dept Radiat Sci, Umea, Sweden
来源：
NEURO-ONCOLOGY | 2013年 / 15卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：28 / 29
页数：2
相关论文
共 50 条
  • [31] Receptor Tyrosine Kinase Signaling and Targeting in Glioblastoma Multiforme
    Tilak, Manali
    Holborn, Jennifer
    New, Laura A.
    Lalonde, Jasmin
    Jones, Nina
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (04) : 1 - 35
  • [32] Mechanism of Mer receptor tyrosine kinase inhibition of glomerular endothelial cell inflammation
    Zhen, Yuxuan
    Finkelman, Fred D.
    Shao, Wen-Hai
    JOURNAL OF LEUKOCYTE BIOLOGY, 2018, 103 (04) : 709 - 717
  • [33] LRIG1 is a pleiotropic androgen receptor-regulated feedback tumor suppressor in prostate cancer
    Li, Qiuhui
    Liu, Bigang
    Chao, Hsueh-Ping
    Ji, Yibing
    Lu, Yue
    Mehmood, Rashid
    Jeter, Collene
    Chen, Taiping
    Moore, John R.
    Li, Wenqian
    Liu, Can
    Rycaj, Kiera
    Tracz, Amanda
    Kirk, Jason
    Calhoun-Davis, Tammy
    Xiong, Jie
    Deng, Qu
    Huang, Jiaoti
    Foster, Barbara A.
    Gokhale, Abhiram
    Chen, Xin
    Tang, Dean G.
    NATURE COMMUNICATIONS, 2019, 10 (1)
  • [34] The soluble form of pan-RTK inhibitor and tumor suppressor LRIG1 mediates downregulation of AXL through direct protein-protein interaction in glioblastoma
    Neirinckx, Virginie
    Hau, Ann-Christin
    Schuster, Anne
    Fritah, Sabrina
    Tiemann, Katja
    Klein, Eliane
    Nazarov, Petr, V
    Matagne, Andre
    Szpakowska, Martyna
    Meyrath, Max
    Chevigne, Andy
    Schmidt, Mirko H. H.
    Niclou, Simone P.
    NEURO-ONCOLOGY ADVANCES, 2019, 1 (01)
  • [35] LRIG1 is a pleiotropic androgen receptor-regulated feedback tumor suppressor in prostate cancer
    Qiuhui Li
    Bigang Liu
    Hsueh-Ping Chao
    Yibing Ji
    Yue Lu
    Rashid Mehmood
    Collene Jeter
    Taiping Chen
    John R. Moore
    Wenqian Li
    Can Liu
    Kiera Rycaj
    Amanda Tracz
    Jason Kirk
    Tammy Calhoun-Davis
    Jie Xiong
    Qu Deng
    Jiaoti Huang
    Barbara A. Foster
    Abhiram Gokhale
    Xin Chen
    Dean G. Tang
    Nature Communications, 10
  • [36] Elucidating the Activating Mechanism of Gatekeeper Mutations on Receptor Tyrosine Kinases
    Besch, Alida
    Marsiglia, William
    Mohammadi, Moosa
    Zhang, Yingkai
    Traaseth, Nate
    BIOPHYSICAL JOURNAL, 2020, 118 (03) : 53A - 53A
  • [37] miR-20a mediates temozolomide-resistance in glioblastoma cells via negatively regulating LRIG1 expression
    Wei, Junhua
    Qi, Xuchen
    Zhan, Qitao
    Zhou, Daoyang
    Yan, Qingfeng
    Wang, Yirong
    Mo, Lianjie
    Wan, Yingfeng
    Xie, Dajiang
    Xie, Jixi
    Yang, Shuxu
    BIOMEDICINE & PHARMACOTHERAPY, 2015, 71 : 112 - 118
  • [38] A soluble ectodomain of LRIG1 inhibits cancer cell growth by attenuating basal and ligand-dependent EGFR activity
    Goldoni, S.
    Iozzo, R. A.
    Kay, P.
    Campbell, S.
    McQuillan, A.
    Agnew, C.
    Zhu, J-X
    Keene, D. R.
    Reed, C. C.
    Iozzo, R. V.
    ONCOGENE, 2007, 26 (03) : 368 - 381
  • [39] Inhibition of epidermal growth factor receptor-associated tyrosine kinase blocks glioblastoma invasion of the brain
    Penar, PL
    Khoshyomn, S
    Bhushan, A
    Tritton, TR
    NEUROSURGERY, 1997, 40 (01) : 141 - 151
  • [40] LRIG1 is a novel negative regulator of the Met receptor and opposes met and Her2 synergy
    Shattuck, David L.
    Miller, Jamie K.
    Laederich, Melanie
    Funes, Melanie
    Petersen, Heidi
    Carraway, Kermit L., III
    Sweeney, Colleen
    MOLECULAR AND CELLULAR BIOLOGY, 2007, 27 (05) : 1934 - 1946
12345